CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
ADVL1315 COG A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA; 123101) in Children with Recurrent or Refractory Solid Tumors Pediatric CIRB
ADVL1412 COG A Phase 1/2 Study of Nivolumab (IND# 124729) in Children; Adolescents; and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Pediatric CIRB
ADVL1414 COG A Phase 1 Study of Selinexor (KPT-330; IND #125052); A Selective XPO1 Inhibitor; In Recurrent and Refractory Pediatric Solid Tumors; Including CNS Tumors Pediatric CIRB
ADVL1416 COG A Phase 1 study of Ramucirumab; a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors; including CNS Tumors Pediatric CIRB
ADVL1513 COG A Phase 1 Study of Entinostat; An Oral Histone Deacetylase Inhibitor; In Pediatric Patients with Recurrent or Refractory Solid Tumors; Including CNS Tumors and Lymphoma Pediatric CIRB
ADVL1514 COG A Phase 1 Study of ABI-009 (nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan Pediatric CIRB
ADVL1515 COG A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors Pediatric CIRB
ADVL1521 COG A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia Pediatric CIRB
ADVL1522 COG A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953; NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor; Rhabdomyosarcoma; Neuroblastoma; Pleuropulmonary Blastoma; Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Pediatric CIRB
ADVL1614 COG A Phase 1/2 Study of VX15/2503 (IND #136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Pediatric CIRB